Quant Small Cap Fund reshuffled its portfolio in April, exiting seven stocks including HDFC Bank and Jio Financial Services while adding ne...

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...

Most investors live by one ratio. That ratio that tells them all they want to know – or should one say all they want to hear? They open a s...

Markets face a tricky situation with rising crude oil, a weakening rupee, and increasing global interest rates. Varun Saboo advises ignorin...

Geopolitical tensions, particularly the Iran crisis, are overshadowing strong corporate earnings, according to Dipan Mehta. While India Inc...

Indian stock markets experienced a significant downturn on Monday. The Sensex and Nifty saw sharp declines as oil prices surged. Fading hop...

India's drug regulator has issued a new directive for pharmaceutical companies. Periodic Safety Update Reports for new drugs must now be su...

Markets are pricing in a swift conflict resolution, but elevated energy costs will impact corporate margins in the near term. While earning...

India has eased Foreign Direct Investment rules for companies with up to ten percent Chinese or Hong Kong shareholding. These firms can now...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

Indian enterprises are navigating challenges posed by the Goods and Services Tax. The inverted duty scenario is particularly affecting FMCG...

Sun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...

Indian authorities are increasing vigilance on popular weight loss drugs. Indian Pharmacopoeia Commission will now compile reports on adver...

Health issues can lead to financial crises. UCPMP tackles unethical practices like Dolo-650 controversy, CBDT accusations. Requires support...

A high-level committee formed under Niti Aayog's VK Paul held a meeting on Friday with the representatives of pharma lobby groups to review...

The panel includes secretary of the department of pharmaceuticals S Aparna, Union health secretary Rajesh Bhushan, and Central Board of Dir...

The minister said there were reports in newspapers that some unethical marketing practices were being followed by certain pharma companies.